NCT03934229 (QLSlimCapHL) is a NA clinical trial of Daily intake of study product in Overweight, sponsored by Danisco France SAS.

Who is sponsoring NCT03934229?

NCT03934229 is sponsored by Danisco France SAS.

What drugs are being tested in NCT03934229?

Interventions in NCT03934229: Daily intake of study product.

What condition does NCT03934229 study?

NCT03934229 studies Overweight, Obesity.

Is NCT03934229 still recruiting?

NCT03934229 is currently completed. Last updated 12 October 2022.

Last reviewed 2022-10-12 · How we verify

NCT03934229: QLSlimCapHL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Study Probiotics on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention

Completed NA Last updated 12 October 2022

What this trial tests

NA trial testing Daily intake of study product in Overweight in 418 participants. Completed in 14 January 2022.

Timeline

22 October 2019

Primary endpoint
14 January 2022

14 January 2022

Quick facts

Lead sponsor	Danisco France SAS
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	418
Start date	22 October 2019
Primary completion	14 January 2022
Estimated completion	14 January 2022
Sites	7 locations across France, Spain

Drugs / interventions tested

Daily intake of study product

Conditions studied

Overweight — all drugs for Overweight →
Obesity — all drugs for Obesity →

Sponsor

Danisco France SAS

Who can join

Adults 20 to 65, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, placebo-controlled, multi-center, parallel group study on overweight and obese individuals following healthy lifestyle consisting of calorie-reduced diet (20% calorie restriction) and increase in daily activity (1000 steps more per day once compared to the baseline steps)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overweight

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03934229 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danisco France SAS
Last refreshed: 12 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03934229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing